NuCana Registered Forum: Community User: Marimon

wann kommt 2025

2024

ey Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of March 31, 2024, NuCana had cash and cash equivalents of £12.9 million compared to £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £6.8 million for the quarter ended March 31, 2024, as compared to a net loss of £7.9 million for the quarter ended March 31, 2023. Basic and diluted loss per share was £0.13 for the quarter ended March 31, 2024, as compared to £0.15 per share for the comparable quarter ended March 31, 2023. “Our focus remains on advancing our innovative ProTide pipeline to develop more efficacious and safer medicines for patients with cancer,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “NUC-3373, a transformation of 5-FU, is currently being investigated in three ongoing clinical studies. Our randomized Phase 2 study (NuTide:323) is now fully enrolled with 182 patients, and compares NUC-3373 in combination with irinotecan, leucovorin and bevacizumab (NUFIRI + bev) with the standard of care, 5-FU in combination with irinotecan, leucovorin and bevacizumab (FOLFIRI + bev) for the second-line treatment of patients with metastatic colorectal cancer. We look forward to announcing initial data from this study in 2024. We also plan to announce additional data from our ongoing Phase 1/2 study (NuTide:302) of NUFIRI + bev and NUFOX + bev in patients with metastatic colorectal cancer this year. Our Phase 1b/2 study (NuTide:303) of NUC-3373 in combination with pembrolizumab in patients with solid tumors and in combination with docetaxel in patients with lung cancer also remains on track with data readouts expected in 2024.” Mr. Griffith continued: “Moving to NUC-7738, we recently presented exciting data at the American Association of Cancer Research (AACR) Annual Meeting. These data highlighted NUC-7738’s ability to disrupt RNA polyadenylation, leading to profound alterations in the tumor biology of the patients’ cancers. We believe that this finding provides a rationale as to why NUC-7738 plus pembrolizumab has achieved encouraging anti-cancer activity in several patients who were resistant to PD-1 inhibitors. We are evaluating NUC-7738 in an ongoing Phase 1/2 study (NuTide:701) as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in PD-1 inhibitor-resistant patients with melanoma. We plan to announce additional data from this study in 2024.” Mr. Griffith concluded, “We look forward to providing updates from all of our ongoing clinical studies this year as we continue working towards our mission of improving treatment outcomes for patients with cancer.”

Was ein Traum EK

Hoffe ich sehe meinen EK von 0,058 wenigstens wieder. Trau dem ganzen nicht

Denke viele sind jetzt ängstlich wegen des Abfalls. Aber wenn wir erstmal nächste Woche deutlich höher sind, dann dürfte es wieder steil nach oben. Gehen. Daher habe Ihnen mich jetzt direkt am Anfang eingekauft

Ja. Komplett irre. Das war einfach ein übertriebener abverkauf

Noch besser war der RS und da hatte ich EK den keiner wissen will .

ich hab ja jetzt schon n bissl gelesen und recherchiert aber warum die aktie innerhalb von 10 tagen von 1,1 dollar auf 3 cent knallt...das hab ich noch immer nicht kapiert

700 Mio Nasdaq läuft

Vielen Dank für die Info.

es scheint das du nicht gewählt bist Infos zu suchen, hier wurde letzte Woche mehrfach der Grund gepostet. Offering

Ach wie dumm von mir zu glauben das man sich hier aus tauscht.

Lauter rote Kerzen 😜

Wird jetzt gnadenlos nach unten geshortet

Sicher nicht